瑞士诺华制药的管理层显然和他们的同胞——食品巨头雀巢越发亲密了。
EXECUTIVES at Novartis, a Swiss pharmaceuticals firm, are certainly getting chummy with their compatriots at nestle, a food giant.
辉瑞和诺华制药已经设立了各自的生物科技部门，爱力根也一定会紧跟其后。
Pfizer and Novartis have formed their own biotech divisions, and Allergan will surely follow.
诺华制药美国发言人周一晚间说，无法联系到身处瑞士的魏思乐做出置评。
U. S. spokeswoman for Novartis said late Monday that Mr. Vasella couldn't be reached for comment in Switzerland.
诺华制药以每股168美元的报价实现了全额收购，如有必要还将提供现金贴补。
The payment will be a combination of Novartis stock and, if necessary, cash to bring the value of the bid to $168 a share.
诺华制药已经在上海建立了一个科研中心，另外，诺华还在新加波开设了一家热带疾病研究所。
Novartis has opened a research centre in Shanghai and has another outpost in Singapore focused on tropical diseases.
诺华制药和它的竞争者们希望在增强已有业务的同时，进军生物科技、非处方药以及医疗器械等领域。
Novartis, like many of its competitors, wants to beef up its own generics business as well as moving further into biotechnology, non-prescription drugs and medical devices.
瑞士诺华制药公司认为，药片不应只向血流中输送药物，还应该能够监测其效果，并把数据传送给医生。
Swiss pharma house Novartis thinks pills needn't merely deliver medicine to the bloodstream, but could also monitor its effects and transmit data to physicians.
制药板块跌幅有限，诺华制药公司表示将完成对爱尔康集团的收购，终结和少数股东长达11个月的纷争。
Drugmakers limited declines after Novartis AG said it will take full control of Alcon Inc., ending an 11-month dispute with minority shareholders.
瑞士药业巨头诺华制药（Novaritis）去年耗资57亿美元，并购了凯龙公司（Chiron）。
Novartis, a Swiss drugs giant, paid some $5.7 billion to finalise its acquisition of Chiron last year.
包括基因泰克和诺华制药在内的一些制药公司正在研究可以进入细胞内部并阻断VEGF的小分子抗癌药物。
But a number of drug companies including Genentech and Novartis AG are looking at small molecule cancer drugs that can get inside cells and block VEGF.
由于需要呼吸系统疾病药物常规使用又难于生产的吸入剂装置，直到最近，诺华制药股份有限公司才掌控该技术。
Until recently, Novartis was not on the radar as a major force in lung drugs which are typically difficult to make because of the inhaler devices needed.
根据世界卫生组织(世卫组织)与诺华制药有限公司今天签署的一项协议，世界所有麻风患者将继续受益于免费药物。
All leprosy patients in the world will continue to benefit from free medicines under an agreement signed today by the world Health Organization (WHO) and the pharmaceutical company, Novartis ag.
这为疫苗研发者提供了更多免疫靶点，从而促使其开发出更多疫苗品种，比如诺华制药新推出的乙型脑膜炎病毒疫苗。
This increased the number of targets available to vaccine developers and led directly to the development of Novartis's new meningitis-B vaccine, for example.
诺华制药的老总魏思乐博士坚决拥护近来的并购。但是也承认大公司现在必须去公司外找灵感，因为“我们无法面面俱到。”
Dr Vasella, Novartis's boss, stoutly defends recent mergers, but accepts that big firms must now look outside for inspiration because “we can't do it all ourselves.”
瑞士诺华制药公司股价上涨6.4%，至57.05瑞士法郎，诺华制药同意以129亿美元的价格收购眼部护理企业爱尔康公司的剩余股权。
Novartis rallied 6.4 percent to 57.05 Swiss francs after the company agreed to pay $12.9 billion for Alcon stock it doesn’t already own.
对制药巨头诺华公司（Novartis）来说，2011年上半年的收入以美元衡量增长9%，但是以瑞士法郎衡量则亏损16%。
For Novartis, a pharmaceuticals giant, a 9% earnings gain in dollar terms during the first half of 2011 turned into a 16% loss in Swiss-franc terms.
希望其他的制药公司也能仿效诺华公司的做法即使它们和瑞士公司没有什么特殊联系。
Even if they do not have any special Swiss connections, expect other drugs firms to follow Novartis's lead.
瑞士制药企业诺华公司认为药片不仅需要把药物送至血管，还应能够监测药效，把相关数据传送给医生。
Swiss pharmacy house Novartis thinks pills needn't merely deliver medicine to the bloodstream, but could also monitor its effects and transmit data to physicians.
瑞士制药巨头诺华公司目前卷入两笔交易。
NOVARTIS, a Swiss pharmaceuticals giant, is involved in two deals at the moment.
据报道，过去四年中，由于手表制造商斯沃琪集团，雀巢以及制药公司诺华股份有限公司的拉动，瑞士前30强公司收益增长率高达38%。
The 30 largest Swiss companies reported earnings growth of 38 percent during the past four years, buoyed by exports from watchmaker Swatch Group AG, Nestle and drugmaker Novartis AG.
在中国开展药物研究的其他主要制药公司包括诺华，阿斯利康，辉瑞，葛兰素史克和罗氏。
Other major drug companies with a research presence in China include Novartis AG, AstraZeneca Plc, Pfizer inc., GlaxoSmithKline and Roche Holding AG.
全球制药巨头诺华也在我国设研发中心，目标直指中草药研发。
Global pharmaceutical giant Novartis has set up R & D center in China, Chinese herbal medicine research and development directed at targets.
诺华赛分离技术（上海）有限公司提供整体的工艺，设备，研发服务，以及工艺和产品开发，服务于工业生物技术，医药和生物制药行业。
Novasep Asia offers complete processes, equipments, R&D services, and Process and Product Development, for the Industrial Biotech, pharmaceutical, and biopharmaceutical industries.
诺华赛产品的应用范围包括医药、生物制药、食品、功能添加剂和工业生物市场。
The applications of Novasep offering cover the pharmaceutical, biopharmaceutical, food, functional ingredients and bio-industries markets.
制药公司诺华(Novartis)在2014年进行的一项研究显示，它似乎可以增强老年病人的免疫系统。
In a 2014 study by the drug company Novartis, the drug appeared to bolster the immune system in older patients.
制药公司诺华(Novartis)在2014年进行的一项研究显示，它似乎可以增强老年病人的免疫系统。
In a 2014 study by the drug company Novartis, the drug appeared to bolster the immune system in older patients.
应用推荐